Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Entrada Therapeutics (TRDA) Consolidated Net Income: 2022-2024

Historic Consolidated Net Income for Entrada Therapeutics (TRDA) over the last 3 years, with Dec 2024 value amounting to $65.6 million.

  • Entrada Therapeutics' Consolidated Net Income fell 215.75% to -$44.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$103.5 million, marking a year-over-year decrease of 288.29%. This contributed to the annual value of $65.6 million for FY2024, which is 1087.80% up from last year.
  • As of FY2024, Entrada Therapeutics' Consolidated Net Income stood at $65.6 million, which was up 1,087.80% from -$6.6 million recorded in FY2023.
  • Over the past 5 years, Entrada Therapeutics' Consolidated Net Income peaked at $65.6 million during FY2024, and registered a low of -$94.6 million during FY2022.
  • Over the past 3 years, Entrada Therapeutics' median Consolidated Net Income value was -$6.6 million (recorded in 2023), while the average stood at -$11.9 million.
  • Data for Entrada Therapeutics' Consolidated Net Income shows a peak YoY soared of 1,087.80% (in 2024) over the last 5 years.
  • Yearly analysis of 3 years shows Entrada Therapeutics' Consolidated Net Income stood at -$94.6 million in 2022, then spiked by 92.98% to -$6.6 million in 2023, then skyrocketed by 1,087.80% to $65.6 million in 2024.